Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Table 2 Factors for predicting the response of portal vein tumor thrombosis

Factors		Responder	Non-responder	P-value
		CR + PR (n = 15)	SD + PD (n = 20)
Age (yrs)	≤60	7	14	0.163
	>60	8	6
Gender	Male	12	16	1.000
	Female	3	4
ECOG	1	8	10	0.845
	2	7	10
Etiology	Viral	13	17	0.889
	Non-viral	2	3
Child-Pugh classification	A	15	13	0.010
	B	0	7
JIS score	2	14	12	0.026
	3	1	8
Pretreatment AFP (ng/ml)	≤ 20	5	5	0.589
	> 20	10	15
Type of HCC	Nodular	10	10	0.324
	Diffuse infiltrative	5	10
Multiplicity	Solitary	8	16	0.093
	Multiple	7	4
Location of thrombi	PV branch	9	8	0.241
	Main portal trunk	6	12
BED (Gy₁₀, mean ± SD)		70.0 ± 6.5	68.1 ± 11.0	0.530

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group; JIS, Japan integrated staging; AFP, α-fetoprotein; HCC, Hepatocellular carcinoma; PV, Portal vein; BED, biologically effective dose; SD, standard deviation.
P-values are obtained by chi-square test, Fisher’s exact test, or t-test.

ISSN: 1748-717X